Compare Novo Nordisk A/S (NVO) vs Uranium Energy Corp (UEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Uranium Energy Corp — how do they compare? Novo Nordisk A/S trades at $44.72 (market cap $200.69B), while Uranium Energy Corp trades at $11.74 (market cap $5.88B). The key difference: Novo Nordisk A/S is far larger — about 34.1× Uranium Energy Corp's market cap, and Novo Nordisk A/S pays a 3.98% dividend while Uranium Energy Corp pays none. Which is the better fit depends on your goals.
| NVO | UEC | |
|---|---|---|
Market Cap | $200.69B | $5.88B |
Sector | Health | Energy |
52-Week High | $63.98 | $20.14 |
52-Week Low | $35.29 | $9.04 |
Enterprise Value | $215.49B | $5.40B |
Dividend Yield | 3.98% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $45.16, down 3.09% today, with bearish technical signals but strong fundamentals. The stock shows robust profitability with 35.35% net margin and 59.82% ROE, supported by consistent earnings beats. Recent developments include positive pediatric obesity trial results for semaglutide and Wegovy pill launch in Germany. Cash flow remains healthy with $10.81B net inflow in 2025, though 2026 projections show a decline.
NVO presents a mixed outlook with strong fundamental metrics offset by technical weakness and competitive pressures. Investment opportunity lies in the expanding GLP-1 market and pipeline developments, while risks include market share loss to Eli Lilly and failed cardiovascular drug trials. Analyst consensus leans bullish with 57.9% buy ratings, but recent prescription slowdown concerns warrant caution.
UEC trades at $11.89, up 3.03% today, showing volatile momentum amid mixed technical signals. The stock faces fundamental challenges with negative profitability (-513.24% net margin) despite revenue of $66.84M in 2025, while analyst sentiment remains strongly bullish with 87.5% buy ratings. Recent news highlights institutional confidence, including BlackRock's $432.68M investment in August 2026, positioning UEC to benefit from nuclear energy tailwinds.
Outlook: High-risk, high-reward play on nuclear energy growth, but current financials show significant losses. Opportunities include sector tailwinds and institutional backing; risks involve persistent unprofitability and execution challenges in scaling operations. Investors should weigh speculative growth potential against fundamental weaknesses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Uranium Energy Corp
Uranium Energy Corp is a leading American uranium mining and exploration company, currently holding the largest resource base and licensed production capacity in the United States. Utilizing low-cost, environmentally friendly In-Situ Recovery (ISR) mining, UEC is a central player in the domestic nuclear fuel supply chain, transitioning from a resource holder to an active producer and refiner to meet the accelerating demand for carbon-free energy.
Read more on UEC →
